It's been nearly two years since the first gene-editing therapy, Casgevy, was approved for sickle cell disease. Just 39 patients worldwide have received it in that time. This is from a Nov. 10 update from manufacturer Vertex:

Over on the other site, gene-editing scientist Lucas Harrington announced a new company to explore "preventive gene editing."

In case you're counting, this is the third startup openly pursuing plans to edit human embryos. More on the company here: www.preventive.bio/blog/announc...

Day 2 of ACIP: The committee just voted 11-1 in favor of tabling the hepatitis B vaccine issue. This was the anticipated vote language:

The National Review, a leading conservative magazine, tells RFK Jr., "Don't abandon mRNA." www.nationalreview.com/2025/08/dont...

The funny thing about this DEI reporting form that was sent to HHS employees yesterday is that literally anyone on the internet can fill it out: forms.office.com/pages/respon...

Hmm, I thought AI was supposed to speed up the FDA's review process?

Former CEO of 23andMe Anne Wojcicki won her company back late Friday with a $305 million offer made through a new nonprofit she established, TTAM Research Institute. Here's what Wojcicki is promising customers: investors.23andme.com/news-release...

(2/3) It's not a new feat. Here's a participant from a 2012 study using a brain-computer interface (BCI) to control a robotic arm to drink from a bottle. See the pedestal and wire on her head? Not exactly ideal for everyday use.